Article

Alcon updates NDA; FDA approves wider treatment range

Alcon, over a 2-day span in late June, filed one new drug application (NDA) with the FDA and received approval for another.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Related Content
Barti Software raises $12M Series A for AI-powered electronic health records for eye care
August 31st 2025

Barti Software raises $12M Series A for AI-powered electronic health records for eye care

3 Things You Should Know About the GA Pipeline
August 31st 2025

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

A study of the progression of sensitivity loss in GA over time using inferred data
August 31st 2025

A study of the progression of sensitivity loss in GA over time using inferred data

3 Things You Should Know About the GA Pipeline
August 31st 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010
August 31st 2025

FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010

Glaucoma techniques advance with innovative viscoelastic delivery
August 31st 2025

Glaucoma techniques advance with innovative viscoelastic delivery

© 2025 MJH Life Sciences

All rights reserved.